Sylvie Assadourian

54, Rue La Boétie
Paris, 75008, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis.

Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis.

Journal: Leukemia

Published: December 17, 2019

A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification.

A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 13, 2017

Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer.

Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer.

Journal: Oncotarget

Published: January 17, 2017

Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies.

Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies.

Journal: Oncology

Published: January 18, 2015

Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer.

Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 21, 2013

Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours.

Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours.

Journal: British journal of cancer

Published: July 14, 2012

Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours: results from the expansion cohort of a phase I study.

Intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours: results from the expansion cohort of a phase I study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 21, 2012

Cabazitaxel in patients with advanced solid tumours: results of a Phase I and pharmacokinetic study.

Cabazitaxel in patients with advanced solid tumours: results of a Phase I and pharmacokinetic study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 09, 2012

Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours.

Phase I dose-escalation study of intravenous aflibercept administered in combination with irinotecan, 5-fluorouracil and leucovorin in patients with advanced solid tumours.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 29, 2012

Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors.

Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 21, 2012

Showing 1-10 of 10

Last Updated: 09/26/2026